Empa Tablet 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.
MFDS item code 202102075 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood sugar in adult patients with type 2 diabetes. It may also be administered alone, and can be combined with metformin, pioglitazone, sulfonylureas, insulin, DPP-4 inhibitor linagliptin, etc. if blood sugar control is insufficient. Special attention should be paid to the occurrence of cardiovascular events in patients with type 2 diabetes accompanied by cardiovascular disease. This medication improves the patient's health by enhancing blood sugar control and contributing to the prevention of complications.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medication should not be administered to patients with allergies to the active ingredient or components. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis. It should not be administered to patients with severely impaired renal function, end-stage renal disease, or those on dialysis. This medication contains lactose, so it should not be used in patients with lactose intolerance or related genetic disorders. Caution should be exercised when administering to patients with reduced kidney function, and dose adjustment or discontinuation may be required based on glomerular filtration rate. Caution should be used in patients with heart failure NYHA class I-II, and it is not recommended for patients NYHA class III-IV. When used in combination with insulin or sulfonylureas, there is an increased risk of hypoglycemia, and adjustments to the doses of these medications may be necessary. Adverse reactions such as hypoglycemia, genital infections, urinary tract infections, increased urination, and reduced fluid volume may occur. In particular, severe ketoacidosis may occur, and if symptoms arise, treatment should be immediately stopped and medical consultation sought. Elderly patients or those at risk of fluid volume loss should be monitored for dehydration or hypotension, and regular kidney function tests are necessary. Severe urinary infections, such as urosepsis and pyelonephritis, have been reported, so prompt evaluation and treatment are needed if infection symptoms occur. Genital fungal infections may occur frequently, so appropriate treatment is necessary if related symptoms arise. During the use of this medication, urine tests may show positive glucose results. Care should be taken while driving or operating machinery, especially when used in combination with insulin or sulfonylureas due to the risk of hypoglycemia. An increased risk of foot amputation has been reported, so foot care should be prioritized. Severe infections such as necrotizing fasciitis may occur rarely, and immediate medical attention should be sought if pain or swelling occurs in the affected area. This medication may interact with other drugs, so inform your healthcare provider if you are taking any other medications. Pregnant women or those planning to conceive are advised not to use this medication, and breastfeeding women should discontinue nursing while using this medication. Safety and effectiveness have not been established in children under 18 years of age, so it should not be used in this population. No specific toxic symptoms have been reported in case of overdose, but appropriate treatment may be required based on clinical condition. This medication should be kept out of the reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or humidity, so it should be stored in a tightly sealed container. The storage temperature should be maintained between 1 degree and 30 degrees Celsius at room temperature to safely preserve the drug's effectiveness for a long time.
Light yellow, bilaterally convex, oval film-coated tablet
10 tablets/box [(10 tablets/PTP×1)], 30 tablets/box [(10 tablets/PTP×3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.